<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathleen Dungan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony DeSantis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1205375">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucagon-like peptide 1 (GLP-1)-based therapies (eg, dipeptidyl peptidase 4 [DPP-4, DPP4] inhibitors, GLP-1 receptor agonists) affect glycemia through several mechanisms, including enhancement of glucose-dependent insulin secretion, slowed gastric emptying, and reduction of postprandial glucagon and food intake  (
         <a class="graphic graphic_table graphicRef51832" href="/z/d/graphic/51832.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately. General discussions of the initial management of blood glucose and the management of persistent hyperglycemia in adults with type 2 diabetes are also presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120430 utd-content-129531">
          (Related Pathway(s):
          <a class="utd-content-120430" href="/pathway/120430?topicRef=96015&amp;source=see_link">
           Diabetes: Initial therapy for non-pregnant adults with type 2 DM
          </a>
          and
          <a class="utd-content-129531" href="/pathway/129531?topicRef=96015&amp;source=see_link">
           Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1205453">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucagon-like peptide 1 (GLP-1) is produced from the proglucagon gene in L cells of the small intestine and secreted in response to nutrients  (
         <a class="graphic graphic_figure graphicRef59551" href="/z/d/graphic/59551.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. GLP-1 exerts its main effect by stimulating glucose-dependent insulin release from the pancreatic islets [
         <a href="#rid2">
          2
         </a>
         ]. It has also been shown to slow gastric emptying [
         <a href="#rid3">
          3
         </a>
         ], inhibit inappropriate post-meal glucagon release, and reduce food intake  (
         <a class="graphic graphic_table graphicRef51832" href="/z/d/graphic/51832.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,4
         </a>
         ]. GLP-1-based therapies, including the dipeptidyl peptidase 4 (DPP-4) inhibitors, do not usually cause hypoglycemia unless combined with therapies that can cause hypoglycemia [
         <a href="#rid5">
          5
         </a>
         ]. GLP-1 is considered an incretin and is one of a family of naturally occurring gut hormones that is released in response to oral food ingestion, but not to intravenous carbohydrate, and stimulates insulin synthesis and secretion. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Gastrointestinal peptides'
         </a>
         .)
        </p>
        <p>
         DPP-4 inhibitors are a class of oral diabetes drugs that inhibit the enzyme DPP-4 [
         <a href="#rid6">
          6
         </a>
         ]. DPP-4 is a ubiquitous enzyme expressed on the surface of most cell types that deactivates a variety of bioactive peptides, including GLP-1 and glucose-dependent insulinotropic polypeptide (GIP); therefore, its inhibition could potentially affect glucose regulation through multiple effects [
         <a href="#rid7">
          7
         </a>
         ]. However, DPP-4 inhibitors have a modest effect on GLP-1 levels and activity compared with GLP-1 receptor agonists. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2643530366">
         <span class="h1">
          SUGGESTED APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H1203032">
         <span class="h2">
          Patient selection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Add-on therapy
         </strong>
         – Dipeptidyl peptidase 4 (DPP-4) inhibitors may be used as add-on therapy for patients with type 2 diabetes who need modest, additional glucose lowering. They are not the preferred agents for patients with cardiovascular or kidney disease, because they do not impart protective effects on cardiovascular and kidney outcomes. (See
         <a class="local">
          'Cardiovascular effects'
         </a>
         below and
         <a class="local">
          'Kidney outcomes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         DPP-4 inhibitor therapy is safe and effective in combination with any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A thiazolidinedione.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basal insulin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A sulfonylurea.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A sodium-glucose cotransporter 2 (SGLT2) inhibitor [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inadequate data are available to support the efficacy of DPP-4 inhibitors in combination with prandial insulin. Combination therapy with glucagon-like peptide 1 (GLP-1) receptor agonists and DPP-4 inhibitors should be avoided as this combination does not provide additive glucose-lowering effects. (See
         <a class="local">
          'Glycemic efficacy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         DPP-4 inhibitors may be a good option for glucose-lowering therapy particularly in patients at high risk of hypoglycemia, including older patients and those with chronic kidney disease. (See
         <a class="local">
          'Efficacy in chronic kidney disease'
         </a>
         below and
         <a class="local">
          'Hypoglycemia and body weight'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Therapeutic options for the management of persistent hyperglycemia in type 2 diabetes are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monotherapy
         </strong>
         – DPP-4 inhibitors are not used as initial therapy for most patients with type 2 diabetes. Rather, initial therapy usually entails dietary change, weight reduction, exercise, and
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         (in the absence of contraindications). In patients who cannot tolerate or have contraindications to metformin (and to other glucose-lowering medications if indicated for cardiovascular or kidney benefit), DPP-4 inhibitors may be considered as monotherapy. Therapeutic options for the initial management of type 2 diabetes are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Choice of initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H240068347">
         <span class="h2">
          Contraindications and precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following contraindications and precautions should be considered when initiating DPP-4 inhibitor therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DPP-4 inhibitors should not be initiated in patients with a history of pancreatitis. (See
         <a class="local">
          'Pancreas'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          Alogliptin
         </a>
         and vildagliptin have been associated with liver toxicity and require additional monitoring during treatment. For patients with underlying liver disease, an alternative DPP-4 inhibitor should be selected. (See
         <a class="local">
          'Monitoring'
         </a>
         below and
         <a class="local">
          'Liver'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who develop a hypersensitivity reaction to any DPP-4 inhibitor should not be treated with another agent in this class. (See
         <a class="local">
          'Skin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          Saxagliptin
         </a>
         and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         have been associated with an increased risk of hospitalization for heart failure. In patients with existing cardiovascular disease (CVD) or high cardiovascular risk, other glucose-lowering medications with cardiovascular benefit (eg, sodium-glucose cotransporter 2 [SGLT2] inhibitors or GLP-1 receptor agonists) are preferred. If circumstances require use of DPP-4 inhibitor therapy, an alternative DPP-4 inhibitor (ie,
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         ) should be selected. If a patient develops heart failure while taking saxagliptin or alogliptin, the DPP-4 inhibitor should be discontinued. Substitution of an alternative agent should be guided by subsequent monitoring of glycemia. (See
         <a class="local">
          'Heart failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1205905">
         <span class="h2">
          Choice of DPP-4 inhibitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          Sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         , and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         are the dipeptidyl peptidase 4 (DPP-4) inhibitors available for the treatment of type 2 diabetes in the United States and many other countries  (
         <a class="graphic graphic_table graphicRef141217" href="/z/d/graphic/141217.html" rel="external">
          table 2
         </a>
         ). Vildagliptin is available in many countries but not in the United States. Few head-to-head trials have been conducted to guide selection of a specific DPP-4 inhibitor, but available data suggest that DPP-4 inhibitors generally have comparable, modest glucose-lowering efficacy [
         <a href="#rid8">
          8
         </a>
         ]. Patient preference and payer coverage are often considerations for selecting a specific agent. (See
         <a class="local">
          'Glycemic efficacy'
         </a>
         below.)
        </p>
        <p>
         If the decision is made to use DPP-4 inhibitor therapy for glucose lowering, we typically choose either
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         or
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         based on data showing the neutral effects of these agents on cardiovascular outcomes including hospitalization for heart failure. (See
         <a class="local">
          'Heart failure'
         </a>
         below.)
        </p>
        <p>
         If DPP-4 inhibitors are used in patients with severe chronic kidney disease (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), we prefer
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         because it is primarily eliminated via the enterohepatic system. (See
         <a class="local">
          'Patients with chronic kidney disease'
         </a>
         below and
         <a class="local">
          'Efficacy in chronic kidney disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H514036580">
         <span class="h2">
          Dosing
         </span>
        </p>
        <p class="headingAnchor" id="H999998414">
         <span class="h3">
          Patients with normal kidney function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing for specific DPP-4 inhibitors can be found in the table  (
         <a class="graphic graphic_table graphicRef141217" href="/z/d/graphic/141217.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. All of the DPP-4 inhibitors are also available in combined formulations [
         <a href="#rid11">
          11-14
         </a>
         ].
        </p>
        <p>
         The DPP-4 inhibitors
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         and
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         are metabolized by cytochrome P450 (CYP) enzymes. For patients taking strong CYP3A4/5 inhibitors (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         )  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ), the lowest dose (2.5 mg) of saxagliptin is recommended [
         <a href="#rid15">
          15
         </a>
         ]. In patients taking medications that induce CYP3A4
         <em>
         </em>
         or P-glycoprotein (eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ), linagliptin should be avoided  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2244591130">
         <span class="h3">
          Patients with chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         in whom a decision has been made to use a DPP-4 inhibitor, we suggest
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         . Linagliptin is primarily eliminated via the enterohepatic system, and no dose adjustment is necessary in patients with kidney impairment.
        </p>
        <p>
         Other DPP-4 inhibitors may also be used in the setting of chronic kidney disease with proper dose adjustment  (
         <a class="graphic graphic_table graphicRef141217" href="/z/d/graphic/141217.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid10">
          10,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H927087536">
         <span class="h2">
          Monitoring
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney
         </strong>
         – Prior to initiation of any DPP-4 inhibitor, serum creatinine should be measured for calculation of eGFR. Thereafter, calculated eGFR should be monitored every three to six months in patients with eGFR ≤45 mL/min/1.73 m
         <sup>
          2
         </sup>
         and approximately every 6 to 12 months in those with eGFR &gt;45 mL/min/1.73 m
         <sup>
          2
         </sup>
         . (See
         <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">
          "Assessment of kidney function", section on 'eGFR from creatinine (primary approach)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver (
         </strong>
         <strong>
          vildagliptin
         </strong>
         <strong>
          and
         </strong>
         <strong>
          alogliptin
         </strong>
         <strong>
          only)
         </strong>
         – Due to reports of liver toxicity with vildagliptin and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         , liver biochemical tests should be evaluated prior to initiation of either agent and at three-month intervals during the first year of therapy [
         <a href="#rid17">
          17
         </a>
         ]. If an increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of three times the upper limit of normal or greater persists, the drugs should be discontinued. (See
         <a class="local">
          'Liver'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H431017560">
         <span class="h1">
          CLINICAL OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H1206170">
         <span class="h2">
          Glycemic efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         All of the dipeptidyl peptidase 4 (DPP-4) inhibitors appear to have similar glycemic efficacy [
         <a href="#rid8">
          8
         </a>
         ] and result in modest improvement in glycated hemoglobin (A1C). They can be used in combination with most other diabetes medications except glucagon-like peptide 1 (GLP-1) receptor agonists due to lack of additive glucose-lowering effects. The efficacy of combined treatment with DPP-4 inhibitors and prandial insulin is uncertain due to limited data.
        </p>
        <p class="headingAnchor" id="H1312835836">
         <span class="h3">
          Efficacy as monotherapy or combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Across trials, DPP-4 inhibitor treatment as monotherapy or in combination with other agents resulted in placebo-adjusted A1C reductions of approximately 0.4 to 0.9 percentage points [
         <a href="#rid8">
          8
         </a>
         ], without substantial differences among specific DPP-4 inhibitors.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monotherapy
         </strong>
         –
         <strong>
         </strong>
         When used as monotherapy, all DPP-4 inhibitors reduce A1C compared with placebo [
         <a href="#rid18">
          18-26
         </a>
         ], with placebo-adjusted A1C reductions of approximately 0.6 to 0.75 percent [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Few DPP-4 inhibitor trials have used an active comparator. In studies of treatment-naïve patients with type 2 diabetes, vildagliptin had similar A1C-lowering efficacy as
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         but was less effective than
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         [
         <a href="#rid27">
          27,28
         </a>
         ]. For example, in a 52-week trial that compared vildagliptin (100 mg daily) with metformin (titrated to 2000 mg daily) in 780 patients with previously untreated type 2 diabetes, metformin led to greater A1C reduction (between-group difference 0.4 percentage points, 95% CI 0.28-0.65) [
         <a href="#rid28">
          28
         </a>
         ]. Goal A1C (&lt;7 percent) was achieved by 45 and 35 percent of participants who received metformin and vildagliptin, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination therapy
         </strong>
         – DPP-4 inhibitors have been tested in combination with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         [
         <a href="#rid28">
          28-38
         </a>
         ], thiazolidinediones [
         <a href="#rid39">
          39-43
         </a>
         ], sodium-glucose cotransporter 2 (SGLT2) inhibitors [
         <a href="#rid44">
          44-46
         </a>
         ], and sulfonylureas [
         <a href="#rid47">
          47-50
         </a>
         ]. Across trials, add-on therapy with a DPP-4 inhibitor led to placebo-adjusted reductions in A1C of approximately 0.4 to 0.9 percentage points [
         <a href="#rid8">
          8
         </a>
         ].
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          Alogliptin
         </a>
         and vildagliptin also have been tested in combination with insulin therapy [
         <a href="#rid51">
          51,52
         </a>
         ], including multiple daily insulin injection regimens. For example, in a 24-week trial in 296 patients with type 2 diabetes suboptimally treated with insulin, the addition of vildagliptin (50 mg twice daily) modestly improved A1C relative to placebo (placebo-adjusted reduction of 0.3 percentage points) [
         <a href="#rid51">
          51
         </a>
         ]. Importantly, participants in this trial administered an average of three daily insulin injections, providing evidence of the safety and modest efficacy of DPP-4 inhibitor therapy when combined with prandial insulin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When baseline A1C is higher, add-on therapy with a DPP-4 inhibitor may not provide sufficient glucose lowering to achieve glycemic targets. For example, among participants with baseline A1C values &gt;8.5 percent, add-on therapy with vildagliptin 50 or 100 mg daily resulted in an A1C of &lt;7 percent in only 7.5 and 16.3 percent of participants, respectively, versus 2.1 percent of participants who received placebo [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Few head-to-head trials have directly compared DPP-4 inhibitors with other agents when used in combination therapy [
         <a href="#rid53">
          53,54
         </a>
         ]. In the five-year GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) comparative effectiveness trial in 5047 patients with type 2 diabetes on
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         monotherapy, add-on therapy with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         was less effective in achieving and maintaining the A1C goal of &lt;7 percent than
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         , or glargine [
         <a href="#rid53">
          53
         </a>
         ]. The GRADE trial is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Without established cardiovascular or kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2495297814">
         <span class="h3">
          Efficacy in chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors are effective in patients with chronic kidney disease [
         <a href="#rid55">
          55-59
         </a>
         ], including those requiring dialysis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          End-stage kidney disease requiring dialysis
         </strong>
         – In patients with end-stage kidney disease requiring dialysis, DPP-4 inhibitors provide similar glucose-lowering efficacy as sulfonylureas. For example, in a 54-week trial in 129 patients with end-stage kidney disease requiring dialysis, participants were randomly assigned to
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         (reduced dose) or
         <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">
          glipizide
         </a>
         treatment in place of their usual oral glucose-lowering agents [
         <a href="#rid55">
          55
         </a>
         ]. Reductions in A1C did not differ significantly between the sitagliptin and glipizide groups (-0.72 versus -0.87 percentage points, respectively). Sitagliptin is more expensive than sulfonylureas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic kidney disease not requiring dialysis
         </strong>
         – When used in combination therapy regimens, DPP-4 inhibitor treatment confers comparable glucose-lowering in individuals with chronic kidney disease and those with normal kidney function. For example, in a trial in 133 patients with type 2 diabetes and estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         (but not requiring dialysis), participants were randomly assigned to receive
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         or placebo, in addition to their previous background glucose-lowering therapy [
         <a href="#rid56">
          56
         </a>
         ]. At 12 weeks, reduction in A1C was greater with linagliptin than with placebo (-0.76 versus -0.15 percentage points, respectively), and this A1C-lowering effect was sustained over one year.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13200853">
         <span class="h2">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Short-term use of a DPP-4 inhibitor in combination with another oral agent does not appear to reduce or increase the risk of adverse atherosclerotic cardiovascular disease (CVD) outcomes [
         <a href="#rid60">
          60-66
         </a>
         ]. However, specific DPP-4 inhibitors may increase the risk of hospitalization for heart failure. The US Food and Drug Administration (FDA) added warnings about the risk of hospitalization for heart failure to the labels of medications containing either
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         or
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ]. The FDA subsequently added warnings regarding the use of all DPP-4 inhibitors in patients at high risk for heart failure [
         <a href="#rid68">
          68,69
         </a>
         ]. The FDA also recommends discontinuation specifically of saxagliptin and alogliptin in patients who develop heart failure and monitoring to determine if alternative therapy for diabetes is required [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Of note, most of the cardiovascular studies to date have been carried out in very high-risk populations to increase the hazard rate for major CVD events and complete the studies in a relatively brief timeframe. Therefore, few data regarding cardiovascular safety or possible benefit are available in lower-risk patients. In one trial in 5047 participants with type 2 diabetes and low baseline CVD risk, the cumulative incidence of prespecified cardiovascular secondary outcomes was generally higher with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         than with
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         but similar to treatment with glargine or
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         over a mean follow-up of five years [
         <a href="#rid71">
          71
         </a>
         ]. The details of the trial are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Without established cardiovascular or kidney disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3336018839">
         <span class="h3">
          Atherosclerotic CVD and cardiovascular mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         In cardiovascular outcomes trials in patients with type 2 diabetes and high cardiovascular disease (CVD) risk, DPP-4 inhibitors have neither increased nor decreased the risk of major cardiovascular or cerebrovascular events.
        </p>
        <p>
         In several placebo-controlled trials with a median follow-up of 18 to 36 months in participants with type 2 diabetes and either existing CVD or high CVD risk, the primary cardiovascular endpoint (usually a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke) occurred in a similar proportion of patients who were randomly assigned to add-on therapy with
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         , or
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         compared with those who received placebo [
         <a href="#rid60">
          60,62,64,65
         </a>
         ].
        </p>
        <p>
         In a cardiovascular outcomes trial that compared
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         with
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         in 6042 patients with type 2 diabetes and elevated cardiovascular risk (median follow-up 6.3 years), the occurrence of the composite outcome (first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was similar in the two groups (11.8 versus 12 percent in the linagliptin and glimepiride groups, respectively; hazard ratio [HR] 0.98, 95% CI 0.84-1.14) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1022832805">
         <span class="h3">
          Heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In trials in patients with high CVD risk followed over a median of 18 to 36 months, treatment with
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         and possibly
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         [
         <a href="#rid60">
          60,63,67
         </a>
         ] but not
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         or
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         [
         <a href="#rid64">
          64,72
         </a>
         ] increased risk of hospitalization for heart failure. For example, in the saxagliptin cardiovascular outcomes trial, patients in the saxagliptin group had a higher frequency of hospitalization for heart failure than those in the placebo group (3.5 versus 2.8 percent, respectively; HR 1.27, 95% CI 1.07-1.51) [
         <a href="#rid60">
          60
         </a>
         ]. Known risk factors for heart failure, including baseline N-terminal pro B-type natriuretic peptide (BNP) elevation, prior heart failure, and chronic kidney disease, were risk factors for heart failure hospitalizations [
         <a href="#rid61">
          61
         </a>
         ]. In a post hoc analysis of the alogliptin cardiovascular outcomes trial, the frequency of hospitalization for heart failure was numerically higher in the alogliptin group than in the placebo group (3.9 versus 3.3 percent, respectively; HR 1.19, 95% CI 0.90-1.58) [
         <a href="#rid63">
          63,67
         </a>
         ].
        </p>
        <p>
         In contrast, in cardiovascular outcomes trials for
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         and
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         , the rate of hospitalization for heart failure did not differ between DPP-4 inhibitor and placebo groups [
         <a href="#rid64">
          64,72
         </a>
         ]. Similarly, in a trial that compared linagliptin with
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         in 6042 patients with type 2 diabetes and elevated CVD risk, hospitalization for heart failure did not differ between the two groups over a median follow-up of 6.3 years [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         In a systematic review and meta-analysis of randomized trials and observational studies examining heart failure outcomes with DPP-4 inhibitor use, the evidence overall demonstrated no increased risk of new-onset heart failure but a slightly increased risk of hospitalization for heart failure in patients with established CVD or multiple CVD risk factors [
         <a href="#rid73">
          73
         </a>
         ]. Whether this risk extends to patients without high CVD risk is unknown.
        </p>
        <p>
         The specific findings in the meta-analysis were as follows [
         <a href="#rid73">
          73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of heart failure
         </strong>
         – A meta-analysis of 38 trials found no significant difference in risk of heart failure with DPP-4 inhibitor or control (placebo or active comparator) treatment (event rates 0.27 and 0.26 percent, respectively), but the evidence was low quality. Observational studies supported findings from the randomized trials but were limited by heterogeneity (eg, patients with or without baseline CVD, different comparator treatments) and provided very low-quality evidence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of hospital admission for heart failure
         </strong>
         – A meta-analysis of five trials provided moderate-quality evidence that DPP-4 inhibitor therapy increased risk of hospitalization for heart failure compared with placebo (event rate 3.4 versus 3.0 percent; odds ratio [OR] 1.13, 95% CI 1.00-1.26). The patients in the included cardiovascular outcomes trials had established CVD or multiple CVD risk factors. Observational studies supported this finding but with very low-quality evidence. In the observational studies, results varied with the use of an active comparator versus placebo control.
        </p>
        <p>
        </p>
        <p>
         Although these data suggest an increased risk of hospitalization for heart failure with DPP-4 inhibitor use, individual trial data indicate that this risk may not be a class effect. The mechanism(s) underlying this increased risk are unknown but would provide important insight into the likelihood of a class effect.
        </p>
        <p class="headingAnchor" id="H2446105760">
         <span class="h2">
          All-cause mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors do not appear to have any effect on all-cause mortality. In a systematic review and meta-analysis of 189 trials, no difference in all-cause mortality was found between any incretin-based drug (DPP-4 inhibitors and GLP-1 receptor agonists) versus control [
         <a href="#rid74">
          74
         </a>
         ]. The meta-analysis did not distinguish between DPP-4 inhibitor- and GLP-1 receptor agonist-associated mortality, and results were heavily weighted by six large, randomized trials in which 92 percent of all deaths occurred. In a subgroup analysis of the DPP-4 cardiovascular outcomes trials, no difference in all-cause mortality was found between DPP-4 inhibitor and placebo groups (6.1 versus 6.0 percent, OR 1.02, 95% CI 0.91-1.14) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         In the subsequent GRADE trial in 5047 patients with type 2 diabetes and low cardiovascular risk, patients who were randomly assigned to
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         had a similar incidence of all-cause mortality over a mean follow-up of five years compared with those who received
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         or glargine [
         <a href="#rid71">
          71
         </a>
         ]. The details of the trial are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Without established cardiovascular or kidney disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3146538821">
         <span class="h2">
          Kidney outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors appear to have an overall neutral effect on risk of diabetes-related kidney disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without preexisting kidney disease
         </strong>
         – DPP-4 inhibitors neither increase nor decrease risk of incident kidney disease relative to other glucose-lowering therapies. The strongest evidence for these neutral effects over longer-term therapy derives from the GRADE trial. In this trial in 5047 patients with type 2 diabetes on
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         monotherapy and with low baseline prevalence of kidney disease, participants were randomly assigned to add-on therapy with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">
          liraglutide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         , or glargine over a mean follow-up of five years [
         <a href="#rid53">
          53,71
         </a>
         ]. The incidence of moderately or severely increased albuminuria or impaired kidney function was similar among the four groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients at high risk for kidney disease
         </strong>
         – In patients at high risk for kidney disease, DPP-4 inhibitors neither promote kidney disease progression nor provide protective effects. In the
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         cardiovascular outcomes trial, 6991 patients with type 2 diabetes and high risk for CV and kidney disease were randomly assigned to linagliptin or placebo, in addition to background glucose-lowering therapy (predominantly
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , sulfonylurea, insulin) [
         <a href="#rid65">
          65
         </a>
         ]. After a median follow-up of 2.2 years, the secondary kidney outcome (composite of end-stage kidney disease, death due to kidney failure, or a sustained decrease of at least 40 percent in eGFR from baseline) did not differ between groups and occurred in 9.4 and 8.8 percent of patients in the linagliptin and placebo groups, respectively (HR 1.04, 95% CI 0.89-1.22).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with preexisting chronic kidney disease
         </strong>
         – In patients with preexisting chronic kidney disease, DPP-4 inhibitor therapy also does not appear detrimental nor beneficial for kidney function. In a trial in patients with type 2 diabetes and eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         (but not requiring dialysis), average eGFR remained overall stable over one year of treatment with either
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         or placebo when added to background glucose-lowering therapy (median change in eGFR -0.8 versus -2.2 mL/min/1.73 m
         <sup>
          2
         </sup>
         , respectively) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The impact of DPP-4 inhibitor therapy on risk and progression of neuropathy and retinopathy is unknown due to insufficient clinical data. In the GRADE comparative effectiveness trial, the incidence of peripheral neuropathy was similar between participants who received DPP-4 inhibitor therapy and those in the other three treatment groups [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2047029663">
         <span class="h2">
          Hypoglycemia and body weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors do not affect body weight or risk of hypoglycemia in the absence of concomitant treatment with insulin or sulfonylureas [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoglycemia
         </strong>
         – DPP-4 inhibitors confer low risk of hypoglycemia when used as monotherapy or in combination with other glucose-lowering medications. In a comparative effectiveness trial in 5047 participants with type 2 diabetes, treatment with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         as add-on therapy to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         led to a low rate of severe hypoglycemia (0.7 percent) over a mean follow-up of five years [
         <a href="#rid53">
          53
         </a>
         ]. Several trials have demonstrated a lower frequency of hypoglycemia with DPP-4 inhibitors than with sulfonylureas when added to metformin monotherapy [
         <a href="#rid31">
          31,53,75
         </a>
         ]. For example, in a two-year trial in 1551 patients with type 2 diabetes on metformin therapy (mean baseline A1C 7.7 percent),
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         treatment led to a lower frequency of hypoglycemia than
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         (7 versus 36 percent of patients, respectively) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with chronic kidney disease, including those requiring dialysis, this low risk of hypoglycemia with DPP-4 inhibitor therapy is also evident [
         <a href="#rid56">
          56
         </a>
         ]. For example, in patients with end-stage kidney disease requiring dialysis, treatment with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         led to a lower frequency of severe hypoglycemia than treatment with
         <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">
          glipizide
         </a>
         (0 versus 7.7 percent, respectively) despite comparable A1C reduction [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Body weight
         </strong>
         – DPP-4 inhibitors are overall neutral with regard to body weight. In a comparative effectiveness trial in 5047 participants with type 2 diabetes, treatment with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         as add-on therapy to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         resulted in a mean body weight loss of 2 kg over a mean follow-up of five years [
         <a href="#rid53">
          53
         </a>
         ]. In trials that compared add-on therapy with a DPP-4 inhibitor or sulfonylurea, DPP-4 inhibitor treatment led to less body weight gain [
         <a href="#rid31">
          31,75
         </a>
         ]. For example, in a trial in 1551 patients with type 2 diabetes on metformin monotherapy, add-on treatment with
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         reduced body weight relative to
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         over two years (-1.4 versus +1.3 kg body weight change, respectively). In a trial that compared
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         monotherapy with a traditional Japanese diet, the diet led to greater body weight loss (change in body mass index [BMI] -0.9 versus -0.1 kg
         <sup>
          /
         </sup>
         m
         <sup>
          2
         </sup>
         with diet and alogliptin, respectively) [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1203087">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dipeptidyl peptidase 4 (DPP-4) inhibitors were well tolerated in short-term studies and in the five-year GRADE trial [
         <a href="#rid53">
          53
         </a>
         ]. Commonly reported side effects include headache, nasopharyngitis, and upper respiratory tract infection [
         <a href="#rid15">
          15,25,77-79
         </a>
         ]. Some [
         <a href="#rid19">
          19,39
         </a>
         ], but not all [
         <a href="#rid18">
          18,29,35
         </a>
         ], studies have reported a slightly increased risk of gastrointestinal side effects with
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         . The long-term safety of DPP-4 inhibitors beyond three to five years of therapy has not been established.
        </p>
        <p class="headingAnchor" id="H1203093">
         <span class="h2">
          Immune function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the DPP-4 inhibitors are relatively specific for glucagon-like peptide 1 (GLP-1), the long-term consequences of DPP-4 inhibition, including effects on other DPP-4 substrates, are unknown. Due to the ubiquitous nature of dipeptidyl peptidase substrates and the variable specificity of DPP-4 inhibitors, each agent within this class will need to be scrutinized individually for drug-specific side effects [
         <a href="#rid80">
          80
         </a>
         ]. The risk of side effects may be higher with less selective DPP-4 inhibitors. Residual crossover with other DPP-4 substrates (particularly with respect to immune function) remains a concern, although this has not been reported in short-term clinical trials.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasopharyngitis
         </strong>
         – A meta-analysis of
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         and vildagliptin studies with available side effect data reported a small increased risk of nasopharyngitis (relative risk [RR] 1.2, 95% CI 1.0-1.4), urinary tract infection (RR 1.5, 95% CI 1.0-2.2), and headache (RR 1.4, 95% CI 1.1-1.7) [
         <a href="#rid77">
          77
         </a>
         ]. A subsequent meta-analysis of trials (18 to 104 weeks duration) comparing a DPP-4 inhibitor (sitagliptin,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         , vildagliptin,
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         ) with placebo (44 trials), a comparator from another class of antidiabetic agents (20 trials), or another DPP-4 inhibitor (3 trials) showed a small increased risk of nasopharyngitis compared with placebo (6 versus 5.3 percent, RR 1.13, 95% CI 0.99-1.29), which was predominantly driven by the sitagliptin subgroup (5.3 versus 4.1 percent; RR 1.35, 95% CI 1.03-1.77) [
         <a href="#rid78">
          78
         </a>
         ]. The risk of upper respiratory and urinary tract infections was not significantly elevated, whereas the risk of dizziness and headache was slightly elevated (8.2 versus 7.5 percent; RR 1.14, 95% CI 1.02-1.26). In the three head-to-head trials, there were no clinically significant differences in adverse effects among DPP-4 inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COVID-19
         </strong>
         – DPP-4 has been implicated in the pathogenesis of coronavirus infections, including coronavirus disease 2019 (COVID-19). However, DPP-4 inhibitors should not be initiated solely for protection against COVID-19 complications. Patients already taking DPP-4 inhibitors should continue therapy during COVID-19 infection unless they develop a new contraindication to treatment. In population-based observational studies, the use of DPP-4 inhibitors was not associated with increased risk of COVID-19 infection or complications [
         <a href="#rid81">
          81-83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some observational studies suggest protective effects of DPP-4 inhibitor use during COVID-19 infection, including reduced mortality [
         <a href="#rid84">
          84,85
         </a>
         ]. No randomized controlled trials have been conducted to compare the use of DPP-4 inhibitors with other diabetes drugs on COVID-19-related outcomes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1203099">
         <span class="h2">
          Pancreas
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors should not be initiated in patients with a history of pancreatitis. Acute pancreatitis has been reported in association with DPP-4 inhibitors, but data are insufficient to determine a causal relationship [
         <a href="#rid86">
          86-91
         </a>
         ]. Pancreatitis should be considered in patients with persistent, severe abdominal pain (with or without nausea), and DPP-4 inhibitors should be discontinued in such patients. If pancreatitis is confirmed, a DPP-4 inhibitor should not be restarted.
        </p>
        <p>
         There have been postmarketing case reports of acute pancreatitis in patients using
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         , and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         [
         <a href="#rid92">
          92-94
         </a>
         ], similar to case reports describing pancreatitis in patients treated with GLP-1 receptor agonists. (See
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Pancreas'
         </a>
         .)
        </p>
        <p>
         Observational studies have reported conflicting results, with some showing no difference in risk of pancreatitis in patients taking GLP-1-based therapies compared with other oral agents [
         <a href="#rid86">
          86,90,95
         </a>
         ] and one showing an increased risk in users versus nonusers [
         <a href="#rid87">
          87
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective cohort study of a claims database, the incidence of acute pancreatitis in
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         users was 5.6 cases per 1000 patient-years, which was similar to the incidence in the control group with diabetes [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a population-based, case-control study, compared with nonuse, use of GLP-1-based therapy (
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         or
         <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">
          exenatide
         </a>
         ) was associated with an increased risk of hospitalization for acute pancreatitis (adjusted odds ratio [OR] 2.07, 95% CI 1.36-3.13) [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Meta-analyses of randomized trials did not identify an increased risk [
         <a href="#rid88">
          88,89
         </a>
         ]. The overall incidence of pancreatitis was low (35 cases among 68,318 patients, 20 in patients taking DPP-4 inhibitors and 15 in the comparator groups) [
         <a href="#rid89">
          89
         </a>
         ]. More carefully designed observational studies are warranted to definitively establish risk and whether risk may vary among specific DPP-4 inhibitors.
        </p>
        <p>
         Increased risks of subclinical pancreatic inflammation, pancreatic cancer, and neuroendocrine tumors also have been reported in
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         users [
         <a href="#rid92">
          92,96-98
         </a>
         ]. A causal relationship has not been established. After a review of currently available data, the US Food and Drug Administration (FDA) and the European Medicines Agency agreed that there was insufficient evidence to confirm an increased risk of pancreatic cancer with use of GLP-1-based therapies [
         <a href="#rid99">
          99-101
         </a>
         ]. However, concerns remain [
         <a href="#rid102">
          102
         </a>
         ], and pancreatic adverse effects will continue to be monitored and reported [
         <a href="#rid99">
          99,101,103
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1203105">
         <span class="h2">
          Liver
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although uncommon, cases of hepatic dysfunction (liver enzyme elevations, hepatitis) have been reported in patients taking vildagliptin and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         [
         <a href="#rid17">
          17,79
         </a>
         ]. As a result, liver biochemical tests should be evaluated prior to initiation of vildagliptin and alogliptin and at three-month intervals during the first year of therapy [
         <a href="#rid17">
          17
         </a>
         ]. If an increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of three times the upper limit of normal or greater persists, the drugs should be discontinued.
        </p>
        <p class="headingAnchor" id="H2902934988">
         <span class="h2">
          Inflammatory bowel disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a population-based study using data from the United Kingdom Clinical Practice Research Datalink, use of DPP-4 inhibitors was associated with an increased risk of inflammatory bowel disease compared with other diabetes drugs (53.4 versus 34.5 per 100,000 person-years, hazard ratio [HR] 1.75, 95% CI 1.22-2.49) [
         <a href="#rid104">
          104
         </a>
         ]. The median duration of follow-up was 3.6 years. The risk peaked after three to four years of use and decreased after more than four years of use. These findings require confirmation and further investigation into possible mechanisms.
        </p>
        <p class="headingAnchor" id="H1203111">
         <span class="h2">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         DPP-4 inhibitors are contraindicated in patients with a history of a serious hypersensitivity reaction after previous exposure [
         <a href="#rid105">
          105
         </a>
         ]. In postmarketing reports,
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         ,
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         , and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         have been associated with hypersensitivity reactions, including anaphylaxis and angioedema, blistering skin conditions (eg, bullous pemphigoid), and Stevens-Johnson syndrome [
         <a href="#rid106">
          106-109
         </a>
         ]. Skin lesions also occurred in normal volunteers given four to six times the proposed therapeutic dose of vildagliptin [
         <a href="#rid110">
          110
         </a>
         ]. Reports of angioedema in association with DPP-4 inhibitors are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">
          "ACE inhibitor-induced angioedema", section on 'Dipeptidyl peptidase-4 inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3563433">
         <span class="h2">
          Musculoskeletal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some DPP-4 inhibitors (
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         , vildagliptin,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         ) have been associated with severe joint pain [
         <a href="#rid111">
          111,112
         </a>
         ]. Other reported musculoskeletal side effects include myalgias, muscle weakness, and muscle spasms. Symptoms have been reported from two days to five months after initiating DPP-4 inhibitors. In most patients, symptoms resolved within a month after discontinuing the drug [
         <a href="#rid113">
          113
         </a>
         ]. Some patients developed recurrent, severe joint pain after restarting the same or a different DPP-4 inhibitor [
         <a href="#rid112">
          112,113
         </a>
         ]. If a patient develops severe and persistent joint pain while taking a DPP-4 inhibitor, the drug should be discontinued and the patient assessed for resolution of symptoms. If symptoms resolve, a different class of diabetes medication should be prescribed. If symptoms do not resolve after one month of drug discontinuation, they are unlikely the result of DPP-4 inhibitor use, and alternative causes for the symptoms should be sought.
        </p>
        <p class="headingAnchor" id="H2920046972">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">
          "Society guideline links: Diabetes mellitus in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1205101">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of action
         </strong>
         – Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of oral diabetes drugs that inhibit the enzyme DPP-4. DPP-4 is a ubiquitous enzyme expressed on the surface of most cell types that deactivates a variety of other bioactive peptides, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). DPP-4 inhibitors could potentially affect glucose regulation through multiple effects  (
         <a class="graphic graphic_table graphicRef51832" href="/z/d/graphic/51832.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Mechanism of action'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1772.html" rel="external">
          "Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus", section on 'Gastrointestinal peptides'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intolerance or contraindications to
         </strong>
         <strong>
          metformin
         </strong>
         – DPP-4 inhibitors are not considered as initial therapy for most patients with type 2 diabetes. DPP-4 inhibitors can be considered as monotherapy in patients with type 2 diabetes who are intolerant of or have contraindications to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         and to other glucose-lowering agents if indicated for cardiovascular or kidney benefit. They may be a good option for glucose-lowering therapy particularly in patients at high risk of hypoglycemia, including older patients and those with chronic kidney disease. (See
         <a class="local">
          'Patient selection'
         </a>
         above and
         <a class="local">
          'Hypoglycemia and body weight'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Initial pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Inadequate glucose lowering on initial therapy
         </strong>
         – DPP-4 inhibitors can be considered as add-on drug therapy for patients who need additional glucose lowering while on any of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A thiazolidinedione
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Basal insulin
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A sulfonylurea
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A sodium-glucose cotransporter 2 (SGLT2) inhibitor
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Very limited data support the efficacy of DPP-4 inhibitors in combination with prandial insulin. DPP-4 inhibitors and GLP-1 receptor agonists should not be used in combination. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         DPP-4 inhibitors are not the preferred agents for patients with cardiovascular or kidney disease because they do not impart protective effects on cardiovascular and kidney outcomes. The modest glucose-lowering effectiveness and cost of DPP-4 inhibitors temper our enthusiasm for these drugs. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of DPP-4 inhibitor
         </strong>
         – If the decision is made to use DPP-4 inhibitor therapy for glucose lowering, we typically suggest either
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         or
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Our choice is based on data showing the neutral effects of these agents on cardiovascular outcomes including hospitalization for heart failure. The DPP-4 inhibitors appear to have similar glycemic efficacy and result in modest improvement in glycated hemoglobin (A1C). Patient preference and payer coverage are often considerations for selecting a specific DPP-4 inhibitor. (See
         <a class="local">
          'Choice of DPP-4 inhibitor'
         </a>
         above and
         <a class="local">
          'Heart failure'
         </a>
         above and
         <a class="local">
          'Glycemic efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with severe chronic kidney disease (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) in whom a decision has been made to use a DPP-4 inhibitor, we suggest
         <a class="drug drug_general" data-topicid="16490" href="/z/d/drug information/16490.html" rel="external">
          linagliptin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Linagliptin is primarily eliminated via the enterohepatic system and is the only DPP-4 inhibitor that does not require dose adjustment in individuals with impaired kidney function  (
         <a class="graphic graphic_table graphicRef141217" href="/z/d/graphic/141217.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Efficacy in chronic kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – DPP-4 inhibitors are available in both single-agent and combined formulations  (
         <a class="graphic graphic_table graphicRef141217" href="/z/d/graphic/141217.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular and kidney outcomes
         </strong>
         – DPP-4 inhibitors have generally neither reduced nor increased cardiovascular events or the development or progression of kidney disease. Although short-term use of DPP-4 inhibitors in combination with another glucose-lowering agent does not appear to increase risk of adverse atherosclerotic cardiovascular disease (CVD) outcomes,
         <a class="drug drug_general" data-topicid="9534" href="/z/d/drug information/9534.html" rel="external">
          saxagliptin
         </a>
         and
         <a class="drug drug_general" data-topicid="87804" href="/z/d/drug information/87804.html" rel="external">
          alogliptin
         </a>
         may increase risk of hospitalization for heart failure in patients with preexisting CVD or high cardiovascular risk. (See
         <a class="local">
          'Cardiovascular effects'
         </a>
         above and
         <a class="local">
          'Kidney outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Overall, DPP-4 inhibitors are well tolerated. The use of DPP-4 inhibitors has been associated with a slightly increased risk of upper respiratory tract infections. Data are insufficient to determine whether DPP-4 inhibitors increase risk of acute pancreatitis. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther 2011; 2:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014; 63:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273:E981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvo F, Moore N, Arnaud M, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ 2016; 353:i2231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stensen S, Gasbjerg LS, Rosenkilde MM, et al. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes. Diabetes 2022; 71:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther 2014; 5:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2018; 20:1972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alogliptin (nesina) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitagliptin/metformin (Janumet) for type 2 diabetes. Med Lett Drugs Ther 2007; 49:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linagliptin/metformin (Jentadueto) for type 2 diabetes mellitus. Med Lett Drugs Ther 2012; 54:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes. Med Lett Drugs Ther 2011; 53:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheen AJ. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clin Pharmacokinet 2016.
          </a>
         </li>
         <li class="breakAll">
          Bristol-Myers Squibb. Higlights of prescribing information: ONGLYZA (saxagliptin) tablets http://packageinserts.bms.com/pi/pi_onglyza.pdf (Accessed on August 24, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013; 14:259.
          </a>
         </li>
         <li class="breakAll">
          The Electronic Medicines Compendium: Galvus 50 mg tablets http://emc.medicines.org.uk/medicine/20734/SPC/Galvus+50+mg+Tablets/#CLINICAL_PRECAUTIONS (Accessed on October 05, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25:2401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31:2315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med 2007; 24:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30:1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seino Y, Miyata Y, Hiroi S, et al. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab 2012; 14:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010; 33:2406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 2018; 20:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthaei S, Catrinoiu D, Celiński A, et al. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care 2015; 38:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinahones FJ, Gallwitz B, Nordaby M, et al. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab 2017; 19:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009; 11:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022; 387:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ou SM, Shih CJ, Chao PW, et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med 2015; 163:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013; 61:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGill JB, Barnett AH, Lewin AJ, et al. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diab Vasc Dis Res 2014; 11:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019; 322:1155.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm (Accessed on April 19, 2018).
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201280s016lbl.pdf (Accessed on April 19, 2018).
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021995s040lbl.pdf (Accessed on April 19, 2018).
         </li>
         <li class="breakAll">
          http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on April 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           GRADE Study Research Group, Nathan DM, Lachin JM, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022; 387:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation 2019; 139:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016; 352:i610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Li L, Deng K, et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017; 357:j2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. Endocrine 2012; 41:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14:1061.
          </a>
         </li>
         <li class="breakAll">
          http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=87103 (Accessed on February 21, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roussel R, Darmon P, Pichelin M, et al. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. Diabetes Obes Metab 2021; 23:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou JH, Wu B, Wang WX, et al. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases 2020; 8:5576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Belmonte LM, Torres-Peña JD, López-Carmona MD, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med 2020; 18:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirani M, Favacchio G, Carrone F, et al. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care 2020; 43:3042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solerte SB, D'Addio F, Trevisan R, et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care 2020; 43:2999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348:g2366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faillie JL, Azoulay L, Patenaude V, et al. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014; 348:g2780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen RW, Pedersen L, Møller N, et al. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care 2015; 38:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm (Accessed on October 05, 2009).
         </li>
         <li class="breakAll">
          http://packageinserts.bms.com/pi/pi_onglyza.pdf (Accessed on February 21, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azoulay L, Filion KB, Platt RW, et al. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med 2016; 176:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halfdanarson TR, Pannala R. Incretins and risk of neoplasia. BMJ 2013; 346:f3750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013; 346:f3680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62:2595.
          </a>
         </li>
         <li class="breakAll">
          http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&amp;mid=WC0b01ac058004d5c1 (Accessed on August 02, 2013).
         </li>
         <li class="breakAll">
          http://www.medscape.com/viewarticle/808830 (Accessed on August 02, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014; 370:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen D. European drugs agency clashes with scientists over safety of GLP-1 drugs. BMJ 2013; 347:f4838.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm (Accessed on June 14, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrahami D, Douros A, Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018; 360:k872.
          </a>
         </li>
         <li class="breakAll">
          Merck - Highlights of prescribing information: Januvia www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf (Accessed on December 06, 2007).
         </li>
         <li class="breakAll">
          http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm (Accessed on February 21, 2013).
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/201280s009lbl.pdf (Accessed on June 06, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol 2020; 61:e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu SD, Chen WT, Chi CC. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. JAMA Dermatol 2020; 156:891.
          </a>
         </li>
         <li class="breakAll">
          F-D-C reports. The Pink Sheet 2007; 69:10.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarapués M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf 2013; 22:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaicha-Brom T, Yasmeen T. DPP-IV inhibitor-associated arthralgias. Endocr Pract 2013; 19:377.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on August 31, 2015).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 96015 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22127804" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140094" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9374685" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8405741" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27142267" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15978877" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35796651" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement inβ-Cell Function in Patients With Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24664619" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29573110" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715128" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Alogliptin (nesina) for type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17541377" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Sitagliptin/metformin (Janumet) for type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Linagliptin/metformin (Jentadueto) for type 2 diabetes mellitus
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21412207" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039605" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039605" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23289982" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23289982" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17001471" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130196" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355324" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19650754" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16219012" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16823726" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17223217" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205122" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of linagliptin monotherapy on glycaemic control and markers ofβ-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18809631" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17259484" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509069" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130197" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17485570" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17300595" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19478198" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515181" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562200" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17277036" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21059094" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21114605" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22583697" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17157112" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17300592" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21410628" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20724648" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419732" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266675" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26324329" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27762093" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17593236" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19614786" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781152" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19125778" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17387446" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19758359" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36129996" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26457538" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23352379" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23033241" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21977965" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22690943" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24169807" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23992601" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25189213" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23992602" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25765696" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26052984" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30418475" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31536101" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36129997" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30586723" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26888822" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28596247" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22748821" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22249941" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17622601" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22519906" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22519906" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17098089" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33528920" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33344548" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33190637" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33023989" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32994187" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20682680" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440284" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24736555" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23837679" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24764569" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25633664" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21334333" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21334333" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21334333" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27479930" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23751908" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Incretins and risk of neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23748128" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23524641" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23524641" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23524641" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24571751" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23900829" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : European drugs agency clashes with scientists over safety of GLP-1 drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23900829" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : European drugs agency clashes with scientists over safety of GLP-1 drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29563098" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29563098" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29563098" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29563098" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31215644" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32584924" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32584924" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23960039" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Association of musculoskeletal complaints and gliptin use: review of spontaneous reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23598537" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : DPP-IV inhibitor-associated arthralgias.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
